



Tumor Suppressor and Innate Immunity

Guest Editors:

Dr. Markus Vähä-Koskela

Institute for Molecular Medicine
Finland (FIMM), University of
Helsinki, 00100 Helsinki, Finland

Dr. Disha Malani

Institute for Molecular Medicine
Finland (FIMM), University of
Helsinki, 00100 Helsinki, Finland

Deadline for manuscript
submissions:

closed (30 November 2021)

Message from the Guest Editors

The COVID pandemic made the vaccine a buzzword, harnessing the power of one's immunity to fight infections. Although the vaccine is a century-old research area with remarkable successful examples of eradicating infectious diseases such as polio, there are more research opportunities in the field, awaiting more discoveries. As with any other research field, vaccine development also faces challenges. This special issue promotes vaccine research to address the major challenges for advancing the field and broadening the research scope. We believe that nucleic acid vaccines can serve as a powerful weapon against increasing viral infections. Therefore, discovering new vaccines and their possible genotoxic effects will discover more effective vaccines. Along with the development of mainstream vaccinations, we think that technological advancements provide a platform for vaccine development.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com